Developer/Manufacturer | Approach | Doses | Capacity to end 2021 |
---|---|---|---|
Moderna | mRNA | 2 | 950m |
BioNTech/Pfizer | mRNA | 2 | 1,300m |
CanSino Biologics | Adenovirus vector | 1 | N/A |
Johnson & Johnson (Janssen) | Adenovirus vector | 1 | 1,100m |
Oxford/AstraZeneca | Adenovirus vector | 1 | 2,940m |
Novavax | Protein subunit nanoparticle | 2 | 1,350m |
Sinopharm/Wuhan | Inactivated virus | 2 | N/A |
Sinopharm/Beijing | Inactivated virus | 2 | N/A |
Sinovac | Inactivated virus | 2 | 350m |
Gamaleya | Adenovirus vector | 2 | 100m |
Bharat Biotech | Inactivated virus | 2 | N/A |